137 related articles for article (PubMed ID: 20218335)
1. [Theory for prophylactic AIDS vaccine development].
Nomura T; Matano T
Uirusu; 2009 Dec; 59(2):267-75. PubMed ID: 20218335
[TBL] [Abstract][Full Text] [Related]
2. [Analytic and integrative perspectives for HIV vaccine design].
Yamamoto H
Uirusu; 2013; 63(2):219-32. PubMed ID: 25366056
[TBL] [Abstract][Full Text] [Related]
3. [Virological and immunological bases for HIV-1 vaccine design].
Yamamoto H; Matano T
Uirusu; 2007 Dec; 57(2):133-9. PubMed ID: 18357751
[TBL] [Abstract][Full Text] [Related]
4. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
[TBL] [Abstract][Full Text] [Related]
5. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
[TBL] [Abstract][Full Text] [Related]
6. Development of prophylactic AIDS vaccines: the current state of affairs.
Hanke T
Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
[TBL] [Abstract][Full Text] [Related]
7. Dominant induction of vaccine antigen-specific cytotoxic T lymphocyte responses after simian immunodeficiency virus challenge.
Takahara Y; Matsuoka S; Kuwano T; Tsukamoto T; Yamamoto H; Ishii H; Nakasone T; Takeda A; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Sakawaki H; Horiike M; Miura T; Igarashi T; Naruse TK; Kimura A; Matano T
Biochem Biophys Res Commun; 2011 May; 408(4):615-9. PubMed ID: 21531211
[TBL] [Abstract][Full Text] [Related]
8. Toward an AIDS vaccine.
Walker BD; Burton DR
Science; 2008 May; 320(5877):760-4. PubMed ID: 18467582
[TBL] [Abstract][Full Text] [Related]
9. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
GarcĂa-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
10. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
Barouch DH; Santra S; Schmitz JE; Kuroda MJ; Fu TM; Wagner W; Bilska M; Craiu A; Zheng XX; Krivulka GR; Beaudry K; Lifton MA; Nickerson CE; Trigona WL; Punt K; Freed DC; Guan L; Dubey S; Casimiro D; Simon A; Davies ME; Chastain M; Strom TB; Gelman RS; Montefiori DC; Lewis MG; Emini EA; Shiver JW; Letvin NL
Science; 2000 Oct; 290(5491):486-92. PubMed ID: 11039923
[TBL] [Abstract][Full Text] [Related]
11. Development of prophylactic vaccines against HIV-1.
Schiffner T; Sattentau QJ; Dorrell L
Retrovirology; 2013 Jul; 10():72. PubMed ID: 23866844
[TBL] [Abstract][Full Text] [Related]
12. [Development of HIV vaccines].
Shibata R
Nihon Rinsho; 2002 Apr; 60(4):790-7. PubMed ID: 11968790
[TBL] [Abstract][Full Text] [Related]
13. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
Hammond SA; Bollinger RC; Stanhope PE; Quinn TC; Schwartz D; Clements ML; Siliciano RF
J Exp Med; 1992 Dec; 176(6):1531-42. PubMed ID: 1460417
[TBL] [Abstract][Full Text] [Related]
14. Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine.
Kawada M; Tsukamoto T; Yamamoto H; Takeda A; Igarashi H; Watkins DI; Matano T
J Virol; 2007 May; 81(10):5202-11. PubMed ID: 17344296
[TBL] [Abstract][Full Text] [Related]
15. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
Emini EA; Koff WC
Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
[No Abstract] [Full Text] [Related]
16. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.
Barouch DH; Kunstman J; Kuroda MJ; Schmitz JE; Santra S; Peyerl FW; Krivulka GR; Beaudry K; Lifton MA; Gorgone DA; Montefiori DC; Lewis MG; Wolinsky SM; Letvin NL
Nature; 2002 Jan; 415(6869):335-9. PubMed ID: 11797012
[TBL] [Abstract][Full Text] [Related]
17. Development of an AIDS vaccine using Sendai virus vectors.
Ishii H; Matano T
Vaccine; 2015 Nov; 33(45):6061-5. PubMed ID: 26232346
[TBL] [Abstract][Full Text] [Related]
18. [Development of an AIDS vaccine: status report].
Girard MP
Med Trop (Mars); 2007 Aug; 67(4):340-6. PubMed ID: 17926791
[TBL] [Abstract][Full Text] [Related]
19. Preventing AIDS but not HIV-1 infection with a DNA vaccine.
Shen X; Siliciano RF
Science; 2000 Oct; 290(5491):463-5. PubMed ID: 11183769
[TBL] [Abstract][Full Text] [Related]
20. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]